Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Causal effect of tea consumption on the increased risk of puerperal sepsis and the mediation effect of CD25 on IgD- CD38-B cell: A Mendelian randomization analysis.

Medicine·2025
Same author

The Survival Benefits of Chemotherapy for Undifferentiated Carcinoma With Osteoclast-Like Giant Cells of Pancreas: A Retrospective Analysis and Individual Participant Data Meta-Analysis.

Cancer medicine·2025
Same author

Causal associations of tea consumption on risk of pancreatic adenocarcinoma and the mediating role of vascular endothelial growth factor D levels - CORRIGENDUM.

The British journal of nutrition·2024
Same author

Causal associations of tea consumption on risk of pancreatic adenocarcinoma and the mediating role of vascular endothelial growth factor D levels.

The British journal of nutrition·2024
Same author

Comparison of survival outcomes of different treatment modalities for patients with primary splenic diffuse large B cell lymphoma.

Annals of hematology·2023
Same author

A simple and effective method to purify and activate T cells for successful generation of chimeric antigen receptor T (CAR-T) cells from patients with high monocyte count.

Journal of translational medicine·2022

Related Experiment Video

Updated: Jul 8, 2026

A Preclinical Murine Model of Hepatic Metastases
06:51

A Preclinical Murine Model of Hepatic Metastases

Published on: September 27, 2014

29.3K

IND-Enabling Studies for a TCR-T Targeting a Pancreatic Cancer KRASG12V Mutation.

Sizhen Wang1, Guangjie Yu2, Yanzhenzi Dai2

  • 1Research Institute of General Surgery, Jinling Hospital, Affiliated Hospital of Medical School, Nanjing University, Nanjing, China.

Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|June 30, 2025
PubMed
Summary

This study developed a novel TCR-T cell therapy (IX001) targeting the KRAS G12V mutation in pancreatic cancer. Preclinical models show IX001 is safe and effective, supporting clinical trials for HLA-A*11:01 positive patients.

More Related Videos

Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies
09:29

Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies

Published on: September 30, 2016

13.9K
Utilizing High Resolution Ultrasound to Monitor Tumor Onset and Growth in Genetically Engineered Pancreatic Cancer Models
06:57

Utilizing High Resolution Ultrasound to Monitor Tumor Onset and Growth in Genetically Engineered Pancreatic Cancer Models

Published on: April 7, 2018

11.0K

Related Experiment Videos

Last Updated: Jul 8, 2026

A Preclinical Murine Model of Hepatic Metastases
06:51

A Preclinical Murine Model of Hepatic Metastases

Published on: September 27, 2014

29.3K
Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies
09:29

Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies

Published on: September 30, 2016

13.9K
Utilizing High Resolution Ultrasound to Monitor Tumor Onset and Growth in Genetically Engineered Pancreatic Cancer Models
06:57

Utilizing High Resolution Ultrasound to Monitor Tumor Onset and Growth in Genetically Engineered Pancreatic Cancer Models

Published on: April 7, 2018

11.0K

Area of Science:

  • Oncology
  • Immunotherapy
  • Molecular Biology

Background:

  • Pancreatic ductal adenocarcinoma (PDAC) is a significant cause of cancer mortality.
  • KRAS mutations, particularly G12V, are common drivers in PDAC.
  • Adoptive T-cell therapy offers a promising avenue for targeted cancer treatment.

Purpose of the Study:

  • To develop and evaluate a novel T-cell receptor (TCR) engineered T-cell (TCR-T) therapy (051 TCR, designated IX001) targeting the KRAS G12V mutation.
  • To assess the preclinical safety and efficacy of IX001 in an IND-enabling study.
  • To target pancreatic cancer in patients with the HLA-A*11:01 allele, prevalent in the Chinese population.

Main Methods:

  • In vitro characterization of 051 TCR specificity and functionality in T cells from healthy donors.
  • Assessment of tumor reactivity dependent on KRAS G12V mutation and HLA-A*11:01 expression.
  • Good Laboratory Practice (GLP) studies in immunodeficient mice with human pancreatic cancer xenografts to evaluate antitumor efficacy, persistence, safety, and toxicity.

Main Results:

  • IX001 demonstrated potent antitumor effects in preclinical models, with or without IL-2.
  • Retroviral vector integration analysis indicated a low risk of secondary malignancy.
  • No TCR-T-related toxicity or genotoxicity was observed.

Conclusions:

  • IX001 exhibited significant safety and efficacy in a pancreatic cancer xenograft model.
  • The findings support the further clinical development of IX001 for KRAS G12V-mutated pancreatic cancer in HLA-A*11:01 positive patients.